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LETTERS TO THE EDITOR
Critical Care for
Patients with Lung
Cancer
To the Editor:
I read with interest the recently
published concise review by Soubani
and Ruckdeschel,1 which described the
main indications for critical care for pa-
tients with lung cancer and discusses
recent data on their outcome and predic-
tors from which patients with lung can-
cer are likely to benefit.
The outcome of patients with lung
cancer admitted to the intensive care
unit (ICU) has improved. Recently, Tof-
fart et al.2 described 103 consecutive
nonsurgical patients with lung cancer
admitted to three ICUs in France. In this
study,2 patients who had a poor perfor-
mance status (PS) at baseline or who
developed multiorgan failure early after
ICU admission had significantly higher
mortality rates with a survival of 37%
after 90 days.
During the past 3 years, several
studies2–4 have reported the outcomes of
critically ill patients with lung cancer
admitted to ICU. These studies2–4 in-
cluded a total of 347 patients, and the
ICU and in-hospital mortality rate for
these patients were 32% and 47.3%,
respectively. Two of these studies2,3 re-
ported, 144/208 (69.2%) patients with
stages IIIB/IV and 130/208 (62.5%) pa-
tients with metastasis at ICU admission
(n  63)2 or whether already known or
evidenced within the first week of ICU
stay (n  67).3 The factors associated
with increased mortality in this group of
critically ill patients with cancer are
poor PS,2,3 organ dysfunction,2–4 and
metastasis at admission to ICU.2 Specif-
ically, in this subgroup of critically ill
patients with cancer, PS might be a sim-
ple tool for oncologists and intensivists
as an aid for admitting patients with
lung cancer to the ICU.3 On the other
hand, the course of organ dysfunction
during the first 3 days of ICU stay could
be useful for considering treatment lim-
itation.2 The patients in whom potential
benefits from ICU admission are in
doubt should receive a trial of full-code
ICU management; this ICU trial has
been of help for resolving doubts and
conflicts surrounding ICU admission of
patients with cancer.5
Critically ill patients with lung
cancer admitted to the medical ICU
have often posed a high-mortality rate
but their outcome has been progres-
sively improving and is approximating
that of the general critically ill popula-
tion1; however, it should be considered
that early integration of palliative care
with standard oncologic care in patients
with metastatic non-small cell lung can-
cer led to significant improvements in
quality of life and mood.6
Silvio A. N˜amendys-Silva, MD, MSc,
FCCP
Department of Critical Care Medicine
Instituto Nacional de Cancerología
Mexico City, Mexico
Department of Critical Care Medicine
Instituto Nacional de Ciencias Médicas y
Nutrición Salvador Zubirán
Mexico City, Mexico
REFERENCES
1. Soubani AO, Ruckdeschel JC. The outcome
of medical intensive care for lung cancer pa-
tients: the case for optimism. J Thorac Oncol
2011;6:633–638.
2. Toffart AC, Minet C, Raynard B, et al. Use of
intensive care in patients with nonresectable
lung cancer. Chest 2011;139:101–108.
3. Roques S, Parrot A, Lavole A, et al. Six-
month prognosis of patients with lung cancer
admitted to the intensive care unit. Intensive
Care Med 2009;35:2044–2050.
4. Adam AK, Soubani AO. Outcome and prog-
nostic factors of lung cancer patients admitted
to the medical intensive care unit. Eur Respir
J 2008;31:47–53.
5. Darmon M, Azoulay E. Critical care manage-
ment of cancer patients: cause for optimism
and need for objectivity. Curr Opin Oncol
2009;21:318–326.
6. Temel JS, Greer JA, Muzikansky A, et al.
Early palliative care for patients with meta-
static non-small-cell lung cancer. N Engl
J Med 2010;363:733–742.
Do Complex Mutations
of the Epidermal
Growth Factor
Receptor Gene Reflect
Intratumoral
Heterogeneity?
To the Editor:
In our clinical practice, two differ-
ent epidermal growth factor receptor
(EGFR) gene mutations are occasionally
found in a single tumor sample. Such
co-occurring EGFR mutations have
been termed “complex mutations,” and
we have previously reported the incidence
and efficacy of gefitinib for patients with
complex mutations.1 In our previous arti-
cle, we discussed the cause of complex
mutations and speculated on the existence
of intratumoral heterogeneity for EGFR
mutations. We recently encountered three
cases that support our hypothesis and
herein present these cases.
Case 1 was a 68-year-old man.
He received a computed tomography-
guided lung biopsy due to a suspicion of
lung cancer. We performed a fine needle
aspiration, followed by a core needle
biopsy through a guide needle to obtain
both cytological fluid and histological
tissue (Figure 1). Although both cytol-
ogy and histology revealed adenocarci-
noma cells, we accidentally performed
EGFR mutational analysis on both spec-
imens. Interestingly, only a point muta-
tion in exon 21 (L858R) was detected in
the cytology, but complex mutations con-
sisting of a point mutation in exon 18
(G719S) and L858R were detected in the
histology. After a diagnosis of locally ad-
vanced disease, the patient underwent
concurrent chemoradiation therapy. After
the treatment, he has been observed and
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